1 January 2010 in Biochemical Pharmacology
12 June 2014 in Dermatology
JGJuan Antonio Sánchez Gaviño
Juan Antonio Sánchez Gaviño
LMLuis Iñiguez de Onzoño Martín
Luis Iñiguez de Onzoño Martín
Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor and has been approved for the treatment of rheumatoid arthritis (RA) patients who have had an inadequate response to previous biological therapies. Psoriasiform skin lesions, especially palmoplantar pustulosis lesions, are well described following anti-tumour necrosis factor therapy. We describe a 79-year-old woman with rheumatoid factor-positive, anti-citrullinated protein antibody-positive erosive RA, who developed a psoriasiform palmoplantar pustulosis reaction following treatment with TCZ therapy (IL-6 receptor). The rash showed histological features compatible with psoriasis and disappeared following discontinuation of TCZ.
1 November 2006 in Neurobiology of Disease
1 March 2011 in Farmacia Hospitalaria
1 December 2017 in Revista Española de Anestesiología y Reanimación
1 July 2017 in American Journal of Therapeutics
We describe a recent case of Stevens-Johnson Syndrome. A 49-year-old man was admitted to the Intensive Care Unit of an Anaesthesia and Resuscitation Department because of a Fournier gangrene that derived in a sepsis, ventilator-associated pneumonia, and renal failure. He was under treatment with cefepime and suffered a generalized status epilepticus, so started treatment with phenytoin. The next day he developed a “maculous cutaneous eruption in trunk and lower limbs” compatible with a Stevens-Johnson Syndrome. Stevens-Johnson Syndrome is a very severe and potentially fatal multiorganic disease, especially when present in critically ill patients, with a strong drug-related etiology, especially with antiepileptic drugs.